CBD Life Sciences Inc. (CBDL) Applies for Beer & Liquor License to Sell CBD Wine
CBD Life Sciences Inc. (CBDL) Applies for Beer & Liquor License to Sell CBD Wine
Company is creating its own wine. Capitalizing on the projected $2.1 billion U.S. CBD-infused beverage market by 2025, CBDL positions itself at the forefront of innovation, unlocking immense revenue potential in the booming CBD alcohol sector.
公司正在自制紅酒。通過利用到2025年預計將達到21億美元的美國CBD增強飲料市場,CBDL將自己置於創新的前沿,解鎖在蓬勃發展的CBD酒精行業板塊中的巨大營業收入潛力。
SCOTTSDALE, AZ / ACCESSWIRE / November 13, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a pioneer in the CBD wellness industry, is thrilled to announce its application for a beer and liquor license, paving the way for its entry into the CBD-infused wine market. This groundbreaking initiative is set to diversify the company's offerings and tap into one of the fastest-growing segments in the cannabis and alcohol industries.
亞利桑那州斯科茨代爾 / ACCESSWIRE / 2024年11月13日 / CBD Life Sciences Inc. (OTC PINK:CBDL)是CBD健康行業的先驅,很高興宣佈申請啤酒和烈酒許可證,爲其進軍CBD葡萄酒市場鋪平道路。這一開創性舉措旨在使公司的產品多元化,並抓住大麻和酒精行業中增長最快的板塊之一。
Market Opportunity and Revenue Potential
The global cannabis beverage market is flourishing, with a valuation of $1.16 billion in 2023, projected to soar at a compound annual growth rate (CAGR) of 19.2% from 2024 to 2030. In the U.S. alone, the CBD-infused beverage market is expected to exceed $1.4 billion by 2023, demonstrating an enormous demand for innovative, wellness-focused alcohol alternatives.
市場機會與營業收入潛力
全球大麻飲料市場正在蓬勃發展,2023年估值爲11.6億美元,預計在2024年至2030年期間將以19.2%的複合年增長率(CAGR)飆升。僅在美國,CBD增強飲料市場預計到2023年將超過14億美元,顯示出對創新和以健康爲關注的酒精替代品的巨大需求。
The broader cannabis beverage market, including CBD products, is estimated to grow from $4.55 billion in 2021 to a staggering $38.64 billion by 2030, with a CAGR of 27.1%. This trajectory highlights the lucrative potential of CBD-infused wine as an attractive investment and revenue driver for CBDL.
更廣泛的大麻飲料市場,包括CBD產品,預計將從2021年的45.5億美元增長到2030年驚人的386.4億美元,複合年增長率爲27.1%。這一軌跡突顯了CBD增強紅酒的盈利潛力,作爲CBDL一個有吸引力的投資和營業收入驅動因素。
CBDL's Strategic Position
This move into the CBD wine market comes on the heels of a remarkable 1,744% revenue increase for CBD Life Sciences Inc. since February 2024. This growth reflects the company's ability to execute its strategic initiatives and meet consumer demand for premium CBD products effectively. With its beer and liquor license application in process, CBDL is poised to disrupt the wellness and alcohol sectors, further enhancing shareholder value.
CBDL的戰略位置
這一舉措進入CBD紅酒市場的背景是CBD生命科學公司自2024年2月以來營業收入增長了驚人的1744%。這一增長反映出公司能夠有效執行其戰略計劃,並滿足消費對優質CBD產品的需求。CBDL在申請啤酒和酒類許可證的過程中,準備打破健康和酒精板塊的侷限,進一步提升股東價值。
"Applying for a beer and liquor license is a monumental milestone for our company," stated Lisa Nelson, President and CEO of CBD Life Sciences Inc. "We are seizing an opportunity to enter an untapped space that bridges the relaxation of wine with the health benefits of CBD. This initiative represents a massive growth opportunity for CBDL, with the potential to create entirely new revenue streams."
"申請啤酒和酒類許可證是我們公司的一個重要里程碑,"CBD生命科學公司的總裁兼首席執行官麗莎·尼爾森表示。"我們正在抓住一個機會,進入一個未開發的領域,將紅酒的放鬆效果與CBD的健康益處結合起來。這個項目代表了CBDL的一個巨大增長機會,可能創造全新的營業收入來源。"
The Rise of CBD-Infused Beverages
CBD-infused beverages are rapidly becoming a preferred choice for consumers seeking alternative, functional drinks that support relaxation and well-being without the psychoactive effects of THC. According to market research, more than 50% of consumers in the U.S. have expressed interest in trying CBD beverages, including wines, which offer a sophisticated and wellness-oriented drinking experience.
CBD飲料的崛起
CBD飲料正在迅速成爲尋求替代性、功能性飲品的消費首選,這些飲品支持放鬆和健康,而不含THC的精神活性成分。根據市場研究,超過50%的美國消費者表示有興趣嘗試CBD飲料,包括提供優雅且健康飲用體驗的紅酒。
By leveraging its expertise in CBD product formulation, CBDL plans to launch a premium CBD wine line that combines high-quality ingredients with advanced nanotechnology to enhance bioavailability. The product will cater to a growing demographic seeking healthier, holistic lifestyle options.
通過利用其在CBD產品配方的專長,CBDL計劃推出一系列優質CBD紅酒,結合高質量的成分與先進的納米技術,以增強生物利用度。該產品將滿足日益增長的人群對更健康、整體生活方式選擇的需求。
What This Means for Investors
The introduction of CBD-infused wines represents a bold leap forward for CBDL. Industry analysts estimate that cannabis beverages, including CBD-infused options, could account for up to 20% of the overall cannabis market by 2030. This shift could translate into billions of dollars in revenue, solidifying CBDL's leadership in the wellness and CBD industries.
這對投資者意味着什麼
CBD飲料的推出代表了CBDL的一個大膽進步。行業分析師估計,到2030年,包括CBD飲料在內的大麻飲料可能佔整體大麻市場的20%。這一變化可能意味着數十億美元的營業收入,鞏固CBDL在健康和CBD行業的領導地位。
With a focus on premium product innovation, distribution partnerships, and regulatory compliance, CBDL is positioning itself as a dominant player in this burgeoning market. This initiative also lays the groundwork for future expansion into other CBD alcohol categories, such as spirits, seltzers, and beers, amplifying the company's growth potential.
CBDL專注於優質產品創新、分銷合作伙伴關係和合規監管,正在將自身定位爲這一新興市場的主導者。該項目還爲將來進入其他CBD酒精類別(如烈酒、氣泡水和啤酒)奠定了基礎,放大公司的增長潛力。
Consumer and Industry Impact
CBDL's foray into the CBD wine market is expected to resonate strongly with millennials and health-conscious consumers who value authenticity, wellness, and quality in their beverage choices. This new product line will provide consumers with a unique way to enjoy CBD while enhancing their social and relaxation experiences.
消費與行業板塊影響
CBDL進入CBD紅酒市場預計將與重視真實性、健康和品質的千禧一代及健康意識消費者產生強烈共鳴。這條新產品線將爲消費提供一種獨特的享受CBD的方式,同時提升他們的社交和放鬆體驗。
Furthermore, CBD-infused alcohol represents a game-changing opportunity to redefine the wine industry by introducing a wellness-centric alternative to traditional alcoholic beverages. CBDL aims to set a new standard of excellence with its commitment to innovation and quality.
此外,CBD注入的酒精代表着重新定義紅酒行業的變革性機會,通過爲傳統酒精飲料引入一種健康爲中心的替代品。CBDL旨在通過其對創新和質量的承諾設定卓越的新標準。
Looking Ahead
CBD Life Sciences Inc. will provide updates on beer and liquor clients such as restaurants, bars, liquor stores and product launch timeline as milestones are achieved. Shareholders can look forward to seeing this transformative initiative come to life in the months ahead.
展望未來
CBD生命科學公司將提供關於啤酒和酒類客戶的更新,包括餐廳、酒吧、酒類商店和產品發佈時間表,隨着里程碑的實現而更新。股東可以期待在未來幾個月見證這一變革性倡議的實現。
About CBD Life Sciences Inc.
CBD Life Sciences Inc. is a cutting-edge leader in the CBD and wellness industry, offering a diverse range of innovative products designed to enhance consumer health and well-being. From CBD-infused creams to cutting-edge beverages, CBDL continues to push the boundaries of what is possible in the CBD space.
關於CBD生命科學公司
CBD生命科學公司是CBD和健康行業的前沿企業,提供多樣化的創新產品,旨在提升消費的健康與福祉。從CBD注入的面霜到尖端飲料,CBDL持續突破CBD領域可能性的界限。
Follow our social media for the latest updates!
關注我們的社交媒體以獲取最新資訊!
X:
Instagram:
IR Contact: cbdvaultaz@gmail.com
X:
Instagram:
IR聯繫:cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
前瞻性聲明
除了此文中包含的歷史信息外,本新聞稿所討論的事項均爲前瞻性聲明。實際結果可能與前瞻性聲明中描述的結果存在重大差異,並且可能會受到風險和不確定性的影響。請參閱 CBD Life Sciences, Inc. 的 OTC Markets 提交的文件,其中可能指出可能導致實際結果或事件與前瞻性聲明中描述的結果存在重大差異的具體因素。
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Safe Harbor聲明
本發佈包括前瞻性聲明,其基於某些假設並反映管理層當前的預期。這些前瞻性聲明受到許多風險和不確定性的影響,可能導致實際結果或事件與當前預期大相徑庭。其中一些因素包括:全球經濟形勢;一般行業和市場狀況,板塊變化和增長率;我們的戰略和業務計劃能否產生預期的效益存在不確定性;競爭加劇;資本的可獲得性和成本;識別、開發和取得商業成功的能力;爲維護和改善服務質量而需要的支出水平;經濟狀況的變化;法律法規的變化,包括法典和標準、知識產權和稅務事項;或其他未預料到的事項;我們維護和保持戰略關係和分銷協議的能力。公司否認有意或有義務更新或修訂任何前瞻性聲明。公司否認有意或有義務更新或修訂任何前瞻性聲明。
Contact Information:
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
聯繫方式:
莉莎·納爾遜
首席執行官
cbdvaultaz@gmail.com
4802091720
SOURCE: CBD Life Sciences Inc.
來源:CBD Life Sciences Inc.
譯文內容由第三人軟體翻譯。